Education
About Us
Working with TipRanks
Follow Us
Lisata Therapeutics (LSTA)
NASDAQ:LSTA
LSTA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.05 - $4.20
Previous CloseN/A
Volume45.87K
Average Volume (3M)14.03K
Market Cap
$18.10M
Enterprise Value-$6.32M
Total Cash (Recent Filing)$11.42M
Total Debt (Recent Filing)$22.26M
Price to Earnings (P/E)―
Beta0.13
Next Earnings
May 07, 2025EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.40
Shares Outstanding8,620,162
10 Day Avg. Volume9,073
30 Day Avg. Volume14,027
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)20.52
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.35
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.32
Enterprise Value/Ebitda0.28
Forecast
1Y Price Target
$15.00Price Target Upside614.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Lisata Therapeutics News
PremiumCompany Announcements
Lisata Therapeutics’ Earnings Call: Progress Amid Challenges
PremiumCompany Announcements
Lisata Therapeutics Reports 2024 Financial Results and Updates
PremiumCompany Announcements
Lisata Therapeutics Reports 2024 Financial Results and Updates
PremiumPre-Earnings
Is LSTA a Buy, Before Earnings?
PremiumCompany Announcements
Lisata Therapeutics Reports Positive Phase 2 Trial Results---
Bulls Say, Bears Say
Bulls Say
Cash ReservesThe company ended the quarter with $35.9 million in cash, which management believes can cover expenses for all ongoing and proposed trials with runway into early 2026.
Clinical MilestoneThe completion of patient enrollment in the CENDIFOX study marks a significant clinical milestone, with study results expected to provide valuable data on treatment outcomes.
Financial PerformanceLisata announced 3Q24 financial results, posting EPS of ($0.59) compared to our estimate of ($0.77) and consensus of ($0.75).
Bears Say
EarningsLisata announced 3Q24 financial results, posting EPS of ($0.59), indicating a continued trend of losses.
---
Ownership Overview
8.04% Insiders
2.84% Mutual Funds
3.44% Other Institutional Investors
82.62% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
LSTA FAQ
What was Lisata Therapeutics’s price range in the past 12 months?
Lisata Therapeutics lowest stock price was $2.05 and its highest was $4.20 in the past 12 months.
What is Lisata Therapeutics’s market cap?
Lisata Therapeutics’s market cap is $18.10M.
When is Lisata Therapeutics’s upcoming earnings report date?
Lisata Therapeutics’s upcoming earnings report date is May 07, 2025 which is in 32 days.
How were Lisata Therapeutics’s earnings last quarter?
Lisata Therapeutics released its earnings results on Feb 27, 2025. The company reported -$0.55 earnings per share for the quarter, beating the consensus estimate of -$0.76 by $0.21.
Is Lisata Therapeutics overvalued?
According to Wall Street analysts Lisata Therapeutics’s price is currently Undervalued.
Does Lisata Therapeutics pay dividends?
Lisata Therapeutics does not currently pay dividends.
What is Lisata Therapeutics’s EPS estimate?
Lisata Therapeutics’s EPS estimate is -0.53.
How many shares outstanding does Lisata Therapeutics have?
Lisata Therapeutics has 8,620,162 shares outstanding.
What happened to Lisata Therapeutics’s price movement after its last earnings report?
Lisata Therapeutics reported an EPS of -$0.55 in its last earnings report, beating expectations of -$0.76. Following the earnings report the stock price went down -0.833%.
Which hedge fund is a major shareholder of Lisata Therapeutics?
Currently, no hedge funds are holding shares in LSTA
---
Lisata Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (614.29% Upside)
$15.00 (614.29% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.92%
12-Months-Change
Fundamentals
Return on Equity
-51.43%
Trailing 12-Months
Asset Growth
-36.00%
Trailing 12-Months
Company Description
Lisata Therapeutics
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
---
LSTA Company Deck
---
LSTA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in the development of certepetide, including regulatory achievements and a reduction in operating expenses. However, low revenue generation and ongoing net losses pose challenges. The uncertainty surrounding the release of key trial data further complicates the outlook.Read More>---
LSTA Stock 12 Month Forecast
Average Price Target
$15.00
▲(614.29% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Xoma
―
Akebia Therapeutics
―
Clearside Biomedical
―
Applied Therapeutics
―
Best Analysts Covering LSTA
1 Year
1 Year Success Rate
3/13 ratings generated profit
1 Year Average Return
-13.12%
reiterated a buy rating 4 months ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 23.08% of your transactions generating a profit, with an average return of -13.12% per trade.
---